Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes
- DOI
- 10.1007/s13300-026-01864-6
- Published
- 2026-04-08
- Container
- Diabetes Therapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s13300-026-01864-6,
title = {Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes},
author = {Genki Sato and Hiroshi Uchino and Kota Takuma and Manabu Saito and Ayako Fuchigami and Yoko Iwata and Fukumi Yoshikawa and Takahisa Hirose},
year = {2026},
journal = {Diabetes Therapy},
doi = {10.1007/s13300-026-01864-6},
url = {https://doi.org/10.1007/s13300-026-01864-6}
}RIS
TY - JOUR TI - Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes AU - Genki Sato AU - Hiroshi Uchino AU - Kota Takuma AU - Manabu Saito AU - Ayako Fuchigami AU - Yoko Iwata AU - Fukumi Yoshikawa AU - Takahisa Hirose PY - 2026 JO - Diabetes Therapy DO - 10.1007/s13300-026-01864-6 UR - https://doi.org/10.1007/s13300-026-01864-6 ER -
APA
Sato, G., Uchino, H., Takuma, K., Saito, M., Fuchigami, A., Iwata, Y., Yoshikawa, F., & Hirose, T. (2026). Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01864-6
Source records
- crossref · retrieved 2026-09-26T21:49:05.161Z